阿司匹林在动脉粥样硬化性心血管疾病中的临床应用：中国专家共识（2016）

Aspirin use in patients with atherosclerotic cardiovascular disease： the 2016 Chinese expert consensus statement

一、前言 动脉粥样硬化血栓形成（atherothrombosis）是影响心、脑血管和外周动脉的全身系统性病理生理过程，可导致冠状动脉疾病[稳定性冠状动脉疾病（SCAB）、非ST段抬高型急性冠状动脉综合征（NSTE-ACS）和急性sT段抬高型心肌梗死（STEMI）]、

Atherosclerotic cardiovascular disease （ASCVD） is the leading cause of death and has the largest disease burden in China. Aspirin is the most promising agent for the prevention of ASCVD in such a large population for its easy availability and relative effectiveness, although its use in primary prevention is still a subject of debate. The joint task force has reviewed the current evidence of aspirin use in healthy population and in patients with stable coronary artery disease, acute coronary syndrome, transient ischemic attack, stroke and peripheral artery disease. Tile consensus statement provides a practical algorithm for identifying those at a high 10-year ASCVD risk, with more than or equal to 10%, who may benefit from aspirin use. Recommendations for aspirin use in primary and secondary prevention of ASCVD in Chinese, as well as its safety and ＂resistance＂ issues, are ＇also stated.